Psychiatry AtlasMedication guide · United States

Antiseizure medicine; certain products also treat bipolar mania

Valproate preparations (Depakote, Depakote ER)

Generic name
divalproex sodium or valproic acid, delivering valproate
Brand names
Depakote; Depakote ER
Medication class
Antiseizure medicine; certain products also treat bipolar mania
Forms covered
Depakote delayed-release tablets; Depakote ER extended-release tablets; Valproic acid oral capsules

Article updated: 2026-10-30 · Sources last checked: 2026-11-05

Medication Safety Alerts

Look-alike / sound-alike name

  • Depakote can be confused with Depakote ER (U.S. official label). These are different release formulations of the same active medication; their names must not be treated as interchangeable.

High Alert

  • Valproic-acid capsules in community/ambulatory care: dose or formulation errors can cause serious toxicity. Follow the exact product and monitoring plan.

FDA Boxed Warning

Depakote delayed-release tablets; Depakote ER extended-release tablets; Valproic acid oral capsules.

Valproate can cause fatal liver injury, major birth defects, reduced IQ and other neurodevelopmental harm after prenatal exposure, and life-threatening pancreatitis. Liver risk is higher early in treatment, in young children and in people with certain mitochondrial disorders. Pregnancy restrictions depend on the indication. Liver testing and close monitoring are required.

Valproate preparations include divalproex and valproic acid. Their uses, release patterns and dosing differ; pregnancy risks, liver injury and pancreatitis require particular attention.

What to expect: The expected benefit depends on whether the exact product is treating mania, seizures or preventing migraine.

Warning signs · Medicine forms
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Acute bipolar mania; manic or mixed episodes with ER — Adults. Product-specific acute evidence; maintenance requires separate reassessment.Depakote delayed-release tablets; Depakote ER extended-release tablets.
  • Specified seizure disorders — Adults and selected pediatric populations according to product and seizure type. Consult exact age and seizure indication.Depakote delayed-release tablets; Depakote ER extended-release tablets; Valproic acid oral capsules.
  • Migraine prevention — Adults meeting reproductive-safety restrictions. Not acute migraine treatment.Depakote delayed-release tablets; Depakote ER extended-release tablets.

Other uses (off-label)

Off-label means a medicine is prescribed for a use, age group or form that is not included in its FDA approval.

  • Bipolar treatment with valproic acid capsules — Selected patients under clinician supervision. The selected acid-capsule label is for epilepsy; bipolar use is off-label.Valproic acid oral capsules.

What should I expect?

The expected benefit depends on whether the exact product is treating mania, seizures or preventing migraine. Benefit and side effects are followed while the clinician adjusts treatment; sedation can occur before useful improvement.

Follow-up combines symptoms with blood tests when needed. A level in the laboratory’s expected range does not replace checking how you feel or investigating possible toxicity.

How do I take it safely?

Use the prescribed preparation and schedule; delayed-release, extended-release and valproic acid products are not automatically interchangeable. Swallow the covered tablets and acid capsules whole. Food may help stomach upset. Do not use another product’s dose or instructions.

Liver tests, blood counts and platelet or clotting checks are needed before and during treatment, with particular liver monitoring during the first six months. Drug levels may help with changes or suspected toxicity. New confusion or vomiting may need an ammonia test even if liver tests are normal.

Discuss all medicines, especially lamotrigine, topiramate, aspirin, carbapenem antibiotics, methotrexate, estrogen-containing contraception, cannabidiol and sedatives. Valproate is contraindicated in significant liver disease, urea-cycle disorders and specified mitochondrial disorders. Very young children and frail older adults need particular caution.

Pregnancy can involve major birth defects and developmental harm. Migraine prevention is contraindicated in pregnancy and without effective contraception in people who can become pregnant; epilepsy or bipolar use in pregnancy is restricted to situations where alternatives are inadequate. Discuss pregnancy planning, contraception and breastfeeding promptly.

Do not stop abruptly, particularly with epilepsy. Take a missed dose when remembered unless the next is near, then skip it. Never double; contact the team about repeated missed doses or pregnancy.

Do not use this product after a known allergy to its active medicine or ingredients; tell the pharmacist about previous medication reactions.

What side effects should I know about?

  • Gastrointestinal upset, sedation, tremor, weight gain and hair loss.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • Boxed warnings cover potentially fatal liver injury and pancreatitis, and serious fetal or developmental harm during pregnancy. The first six months, children under 2 and specified mitochondrial disorders carry particular liver risk.
  • Severe persistent abdominal pain with vomiting needs urgent assessment for pancreatitis. Jaundice, marked weakness, poor appetite, facial swelling, unusual bleeding or pronounced confusion also needs prompt urgent assessment. High ammonia can cause illness even with normal liver tests.
  • Blistering rash, mouth sores or fever with swollen glands can indicate a dangerous skin or multiorgan reaction. Seek emergency care for a seizure, collapse, serious breathing difficulty, facial or throat swelling, or suspected overdose. Contact the prescriber promptly for new suicidal thoughts, worsening depression or unusual behavior. Use emergency care if there is immediate danger or the person cannot stay safe.

What else should I know to stay safe?

  • Do not use with significant liver disease, urea-cycle disorders, specified mitochondrial disorders or product allergy. Check liver function, blood counts and clotting before and during treatment, with close liver monitoring during the first six months; drug levels or ammonia tests may be needed.
  • Pregnancy planning and reliable contraception are essential. Migraine prevention is contraindicated during pregnancy or without effective contraception in someone who can become pregnant; epilepsy or bipolar use during pregnancy is restricted to situations where alternatives are inadequate. Discuss breastfeeding.
  • Check interactions, particularly lamotrigine, topiramate, aspirin, carbapenem antibiotics, methotrexate, estrogen-containing contraception, cannabidiol and sedatives. Release forms are not automatically interchangeable. Do not stop abruptly, especially with epilepsy; young children and frail older adults need particular care. Pediatric seizure approvals depend on the exact product; Depakote ER seizure uses begin at age 10. Pediatric studies did not establish effectiveness for mania or migraine prevention. Methotrexate or estrogen-containing contraception can lower valproate levels; cannabidiol can increase abnormal liver-test risk. Discuss starts and stops so blood levels, symptoms and liver tests can be monitored.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • Delayed-release and extended-release products may require different total daily amounts. A switch needs the prescriber’s plan, even when the tablets have similar names.
  • Pregnancy planning is central to this medicine, not an optional extra. Risks and acceptable alternatives differ between migraine prevention, epilepsy and bipolar treatment.

How does it work?

Valproate changes several processes involved in nerve-cell activity. One proposed effect is to increase the availability of GABA, a chemical messenger that usually makes nerve cells less likely to fire. This may contribute to its antiseizure effects, but the full explanation for its benefits, including its effects on mood, is still uncertain.

Explore medication science

How was this medicine developed?

Depakote delayed-release tablets were approved in 1983 and Depakote ER in 2000. Different release systems changed administration, while major pregnancy, liver and pancreatic risks remained important across valproate products.

How do I say the name?

Valproate preparations: Valproate: val-pro-ate; valproic acid: val-PROE-ik acid. Capital letters show the stressed syllable.

Medicine forms and official information

Match the full name, release type and route on your prescription. Different formulations need their own prescribing instructions; do not switch or substitute them yourself.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Valproate preparations: current prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.2 Pharmacodynamics; 12.3 Pharmacokinetics..

  2. Valproate preparations: FDA approval history
  3. Valproate preparations: patient medicine information
  4. Depakote ER prescribing information
  5. Valproic acid capsules prescribing information
  6. Depakote ER FDA approval history
  7. Information leaflet about medicine reviews for women and people taking valproate
  8. Valproate preparations: FDA prescribing information
  9. Depakote: Package Insert / Prescribing Information / MOA
  10. DailyMed - VALPROIC ACID capsule, liquid filled
  11. Lamotrigine: prescribing information
  12. Valproate preparations: verified neutral parent, PubChem CID 3121
  13. ISMP List of Confused Drug Names
  14. ISMP List of High-Alert Medications in Community/Ambulatory Care Settings
  15. Depakote ER
  16. Frequently Asked Questions about Labeling for Prescription Medicines | FDA

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top